We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Headquartered in Austin, TX, Luminex Corporation recently announced that its ARIES System and Flu A/B & RSV Assay has been assessed by the Department of Viroscience at Erasmus Medical Center, a Netherland-based consultation center for the World Health Organization on viral infections. The study has also been published in the Journal of Clinical Virology, an international magazine on human virology and virus-induced clinical conditions.
Meanwhile, the current market sentiments of the stock lack luster as Luminex represents a negative one-year return of 1.64%, compared to the S&P 500’s 5.09% over the same time frame. However, Luminex gained almost 0.5% to close at $20.95 following the news.
Coming back to the latest development, the study by Erasmus exclusively highlights the clinical sensitivity and specificity of the ARIES System and Flu A/B & RSV assays. Per management, the study by Erasmus demonstrates the value of the ARIES platform for the molecular diagnostic labs that aims to perform 'out of sync' MDx testing.
Of the recent events, Luminex reported third-quarter adjusted earnings of 6 cents per share, which missed the Zacks Consensus Estimate of 12 cents. In fact, earnings slumped 64.7% on a year-over-year basis.
However, the full-year guidance holds promise for the stock, as Luminex expects revenues in the range of $267–$270 million, up from the previous range of $261–$269 million, reflecting overall growth between 12% and 14% over 2015 levels.
On the Aries platform, Luminex submitted the Group B Strep assay to the U.S. FDA in the last reported quarter. Notably, this will be the third IVD-cleared assay on the Aries system fortifying the company’s foothold in the market.
Apart from the lucrative assay portfolio, Luminex’s collaboration with Nanosphere in the recent past is a significant growth driver. Particularly, the Verigene System of Nanosphere is likely to enhance Luminex’s growth trajectory in the coming quarters, in our view.
Cogentix Medical registered a positive earnings surprise of 100% in the last reported quarter. Notably, the company has a solid one-year return of roughly 76.4%.
CryoLife has a stellar one-year return of roughly 86.9%. In the last reported quarter, the company registered an impressive earnings surprise of 225%.
IDEXX Laboratories represents a solid one-year return of almost 66.8%. The company has a long-term expected growth rate of almost 14.96%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Luminex: Erasmus Assesses ARIES System, Flu A/B & RSV
Headquartered in Austin, TX, Luminex Corporation recently announced that its ARIES System and Flu A/B & RSV Assay has been assessed by the Department of Viroscience at Erasmus Medical Center, a Netherland-based consultation center for the World Health Organization on viral infections. The study has also been published in the Journal of Clinical Virology, an international magazine on human virology and virus-induced clinical conditions.
Meanwhile, the current market sentiments of the stock lack luster as Luminex represents a negative one-year return of 1.64%, compared to the S&P 500’s 5.09% over the same time frame. However, Luminex gained almost 0.5% to close at $20.95 following the news.
Coming back to the latest development, the study by Erasmus exclusively highlights the clinical sensitivity and specificity of the ARIES System and Flu A/B & RSV assays. Per management, the study by Erasmus demonstrates the value of the ARIES platform for the molecular diagnostic labs that aims to perform 'out of sync' MDx testing.
Of the recent events, Luminex reported third-quarter adjusted earnings of 6 cents per share, which missed the Zacks Consensus Estimate of 12 cents. In fact, earnings slumped 64.7% on a year-over-year basis.
However, the full-year guidance holds promise for the stock, as Luminex expects revenues in the range of $267–$270 million, up from the previous range of $261–$269 million, reflecting overall growth between 12% and 14% over 2015 levels.
LUMINEX CORP Price
LUMINEX CORP Price | LUMINEX CORP Quote
Our Take
On the Aries platform, Luminex submitted the Group B Strep assay to the U.S. FDA in the last reported quarter. Notably, this will be the third IVD-cleared assay on the Aries system fortifying the company’s foothold in the market.
Apart from the lucrative assay portfolio, Luminex’s collaboration with Nanosphere in the recent past is a significant growth driver. Particularly, the Verigene System of Nanosphere is likely to enhance Luminex’s growth trajectory in the coming quarters, in our view.
Key Picks
Luminex currently holds a Zacks Rank #2 (Buy).
Favorably-ranked stocks in the broader medical space include Cogentix Medical, Inc. (CGNT - Free Report) , CryoLife Inc. and IDEXX Laboratories, Inc. (IDXX - Free Report) , all of which sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cogentix Medical registered a positive earnings surprise of 100% in the last reported quarter. Notably, the company has a solid one-year return of roughly 76.4%.
CryoLife has a stellar one-year return of roughly 86.9%. In the last reported quarter, the company registered an impressive earnings surprise of 225%.
IDEXX Laboratories represents a solid one-year return of almost 66.8%. The company has a long-term expected growth rate of almost 14.96%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>